Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.
FDA application actionMarch 8, 2022
Oxaliplatin
Approved submission · SUPPL 9
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 29
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 66
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 22
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 54
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 12
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 44
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 28
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 35
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 18
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 21
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 22
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 19
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 2
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 7
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 3
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 4
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Nystatin
Approved submission · ORIG 1
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 24
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 19
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 10
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Omeprazole
Approved submission · SUPPL 8
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →FDA application actionMarch 4, 2022
Dapagliflozin
Approved submission · SUPPL 6
A dated action on a US drug application. It does not establish approval for longevity or describe the approved indication.
Data provided by the U.S. Food and Drug Administration through openFDA, CC0. Not a medical decision tool or approval for longevity. Licence
Inspect the source record →